Pfizer CEO Albert Burla said Monday he was not sure a fourth dose of the Covid-19 vaccine would be needed, and announced that the vaccine against the highly contagious omicron variant would be ready in March.
However, Moderna CEO Stephen Bansell said last week that an additional dose may be needed in the fall, as the booster’s effectiveness is likely to weaken in the next few months.
The huge increase in newly infected people caused by the spread of omicron has forced some countries to consider giving the vaccine an extra dose, but there are indications that revaccination may be difficult to accept as citizens enter the third year of the pandemic, according to Reuters.
“I do not know if a fourth amplifier will be needed, it must be investigated,” Burla told CNBC.
He also added that they are working on a new version of the vaccine against Covid, which will be effective against omicron and other variants.
The US pharmaceutical company has previously announced that it has entered into three contracts for the extended use of RNA technology, on which its vaccine is based, including a contract with the genetic research company “Beam Therapeutics”, worth up to one billion and 350 million dollars.